Portola Pharmaceuticals Inc. (NASDAQ: PTLA) shares more than doubled on Tuesday after the company announced that it would be acquired by Alexion Pharmaceuticals Inc. (NASDAQ: ALXN).
According to the deal, Alexion will pay $18 per Portola share in cash, a premium of 132% to Portola’s last closing price, for an aggregate price of $1.41 billion.
Essentially, Alexion is paying for Portola’s treatment for reversing the effects of blood thinners. The treatment, Andexxa, was approved in the United States in 2018 and had sales of $111.5 million in 2019.
Alexion has been trying to maintain its position as the top dog in the treatment of certain rare blood disorders through a string of acquisitions to increase its pipeline of rare disease drugs.
Last year, Alexion agreed to buy Achillion Pharmaceuticals for $930 million to acquire its rare blood disorder experimental treatments.
Portola stock traded up about 130% on Tuesday to $17.80, in a 52-week range of $5.31 to $36.49. The consensus price target is $19.57.
Alexion stock was down about 4% to $99.30. The 52-week range is $72.67 to $136.51, and the consensus price target is $139.45.
It’s Your Money, Your Future—Own It (sponsor)
Retirement can be daunting, but it doesn’t need to be.
Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.